Methylprednisolone — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.5-1 mg/kg/day (anti-inflammatory); 2-4 mg/kg/day (immunosuppressive)	q12h or q24h	Duration: Variable; taper for long-term therapy Notes: For immunosuppression, may start with higher dose and taper to lowest effective dose.
Dog	IV	30 mg/kg (shock) or 15-30 mg/kg (spinal cord injury)	Single dose or q6h for 24-48 hours	Duration: Short-term (1-2 days) Notes: High-dose pulse therapy for acute conditions.
Cat	PO	0.5-1 mg/kg/day (anti-inflammatory); 2-4 mg/kg/day (immunosuppressive)	q12h or q24h	Duration: Variable; taper for long-term therapy Notes: Cats may be more sensitive to side effects; use lowest effective dose.
Cat	IV	30 mg/kg (shock)	Single dose	Duration: Short-term Notes: High-dose pulse therapy for shock.
Horse	IV	0.5-1 mg/kg (anti-inflammatory)	q24h	Duration: 3-5 days Notes: For respiratory disease, may use 0.5 mg/kg IV q24h.
Horse	Intra-articular	20-40 mg per joint	Single injection	Duration: As needed Notes: For joint inflammation; use strict aseptic technique.
Cattle	IV or IM	0.5-1 mg/kg (anti-inflammatory)	q24h	Duration: 3-5 days Notes: For ketosis, use 0.5-1 mg/kg IV or IM as a single dose.
Small Ruminants	IV or IM	0.5-1 mg/kg (anti-inflammatory)	q24h	Duration: 3-5 days Notes: For pregnancy toxemia, use 1-2 mg/kg IV or IM as a single dose.
Rabbit	PO	0.5-2 mg/kg	q12-24h	Duration: Variable Notes: Use with caution; rabbits are prone to GI stasis.
Bird/Poultry	PO or IM	0.5-2 mg/kg	q12-24h	Duration: Variable Notes: Use with caution; may cause immunosuppression.
Exotic/Other	PO or IM	0.5-2 mg/kg	q12-24h	Duration: Variable Notes: Dose based on species and condition; consult exotic animal references.

Clinical Indications & Species Uses

General Indications

Anti-inflammatory and immunosuppressive therapy for various inflammatory and immune-mediated conditions
Treatment of shock (high-dose, short-term)
Management of allergic reactions

Dog (Canine)

Anti-inflammatory and immunosuppressive therapy for conditions such as allergic dermatitis, asthma, inflammatory bowel disease, immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, lupus erythematosus, and rheumatoid arthritis
Treatment of shock (high-dose, short-term)
Management of spinal cord injury (acute, high-dose)
Adjunct therapy for neoplasia (e.g., lymphoma, mast cell tumors)

Cat (Feline)

Anti-inflammatory and immunosuppressive therapy for allergic dermatitis, asthma, inflammatory bowel disease, immune-mediated diseases (e.g., pemphigus foliaceus), and eosinophilic granuloma complex
Treatment of shock (high-dose, short-term)
Adjunct therapy for neoplasia (e.g., lymphoma)

Horse (Equine)

Anti-inflammatory therapy for musculoskeletal conditions, allergic reactions, and respiratory diseases such as recurrent airway obstruction (heaves)
Treatment of shock (high-dose, short-term)
Management of inflammatory joint disease (intra-articular use)

Cattle (Bovine)

Anti-inflammatory therapy for respiratory disease (e.g., bovine respiratory disease complex), mastitis, and musculoskeletal conditions
Treatment of ketosis (as a glucocorticoid to increase glucose production)
Management of shock (high-dose, short-term)

Small Ruminants (Sheep / Goat)

Anti-inflammatory therapy for respiratory disease, mastitis, and musculoskeletal conditions
Treatment of pregnancy toxemia (as a glucocorticoid to induce parturition or manage metabolic disease)

Rabbit & Small Mammals

Anti-inflammatory and immunosuppressive therapy for allergic conditions, dermatitis, and immune-mediated diseases
Treatment of shock (high-dose, short-term)

Avian & Poultry

Anti-inflammatory therapy for respiratory disease, arthritis, and allergic conditions
Treatment of shock (high-dose, short-term)

Exotic & Other Species

Anti-inflammatory and immunosuppressive therapy for reptiles, small mammals (e.g., ferrets, guinea pigs), and other exotic species
Treatment of shock (high-dose, short-term)

Pharmacology & Mechanism of Action

Drug Class: Corticosteroid | Pharmacological Group: Glucocorticoid

Mechanism of Action: Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor in the cytoplasm, leading to translocation into the nucleus and modulation of gene transcription. It induces the synthesis of lipocortin, which inhibits phospholipase A2, reducing the release of arachidonic acid and subsequent production of prostaglandins, leukotrienes, and other inflammatory mediators. It also suppresses the immune response by inhibiting cytokine production (e.g., IL-1, IL-2, TNF-alpha), reducing leukocyte migration, and decreasing capillary permeability.

Pharmacodynamics: Methylprednisolone has potent anti-inflammatory and immunosuppressive effects. It inhibits the inflammatory response to a variety of inciting agents, including mechanical, chemical, and immunological stimuli. It also has mineralocorticoid activity, but to a lesser extent than hydrocortisone. Its effects are dose-dependent, with higher doses providing more profound immunosuppression. It also affects carbohydrate, protein, and fat metabolism, and can cause gluconeogenesis, protein catabolism, and redistribution of body fat.

⚡ Pharmacokinetics Summary

Absorption: Methylprednisolone is well absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. It is also absorbed systemically after intramuscular and subcutaneous administration, but absorption may be slower and more prolonged. The oral bioavailability is approximately 80-100% in dogs and cats.

Distribution: Methylprednisolone is widely distributed throughout the body. It crosses the placenta and is distributed into milk. It is bound to plasma proteins, primarily corticosteroid-binding globulin and albumin, with a protein binding of about 77%.

Metabolism: Methylprednisolone is metabolized primarily in the liver, mainly by reduction and conjugation. The metabolites are inactive and are excreted in the urine. Some metabolism also occurs in the kidneys.

Excretion: The metabolites of methylprednisolone are excreted primarily in the urine, with a small amount in the feces. The elimination half-life is approximately 1-2 hours in dogs, but the biological half-life is longer (12-36 hours) due to its intracellular effects.

Half-Life: Dog: 1-2 hours (plasma), 12-36 hours (biological); Cat: 1-2 hours (plasma), 12-36 hours (biological); Horse: 1-2 hours (plasma); Cattle: 1-2 hours (plasma)

Bioavailability: Oral: ~80-100% in dogs and cats; IM: variable, but generally well absorbed

Protein Binding: Approximately 77% bound to plasma proteins (corticosteroid-binding globulin and albumin)

Available Formulations & Strengths

Oral Tablet 2 mg, 4 mg, 8 mg, 16 mg, 32 mg (PO)

Injectable Solution 20 mg/mL, 40 mg/mL, 80 mg/mL (IV, IM, SC, Intra-articular)

Oral Suspension 10 mg/5 mL (PO)

Contraindications & Clinical Warnings

Contraindications:

Systemic fungal infections
Known hypersensitivity to methylprednisolone or other corticosteroids
Concurrent use of live vaccines (immunosuppression may impair immune response)
Gastrointestinal ulceration (may exacerbate)
Osteoporosis (long-term use may worsen)
Pregnancy (especially first trimester, unless used for induction of parturition in cattle)

Warnings & Clinical Precautions:

Use with caution in animals with diabetes mellitus, as corticosteroids may increase blood glucose.
Use with caution in animals with congestive heart failure, hypertension, or renal disease due to sodium and water retention.
Long-term use may cause iatrogenic hyperadrenocorticism (Cushing's syndrome).
Abrupt withdrawal after prolonged therapy may cause adrenal insufficiency; taper dose gradually.
Use with caution in animals with infectious diseases, as corticosteroids may mask signs of infection.
In horses, avoid intra-articular injection in infected joints.
In food animals, observe withdrawal times to prevent drug residues in milk and meat.
In birds, use with caution due to increased susceptibility to aspergillosis.
In rabbits, monitor for GI stasis and diarrhea.

Adverse Effects & Reactions

Common:

Increased thirst and urination (polyuria/polydipsia)
Increased appetite (polyphagia)
Panting (especially in dogs)
Weight gain
Lethargy
Gastrointestinal upset (vomiting, diarrhea)

Serious / Severe:

Gastrointestinal ulceration and perforation
Pancreatitis
Iatrogenic hyperadrenocorticism (Cushing's syndrome)
Adrenal suppression
Diabetes mellitus or worsening of existing diabetes
Immunosuppression leading to opportunistic infections
Hepatopathy
Behavioral changes (agitation, aggression)

Rare:

Anaphylactic reactions
Cardiac arrhythmias
Seizures
Osteoporosis and pathologic fractures (long-term use)
Growth retardation in young animals
Cataracts (long-term use)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Nonsteroidal anti-inflammatory drugs (NSAIDs)	Increased risk of gastrointestinal ulceration and bleeding.	High
Furosemide and other loop diuretics	Enhanced potassium depletion, increasing risk of hypokalemia.	Moderate
Insulin or oral hypoglycemic agents	Corticosteroids may increase blood glucose, requiring dose adjustment of antidiabetic medications.	Moderate
Phenobarbital or phenytoin	Increased hepatic metabolism of methylprednisolone, reducing its efficacy.	Moderate
Cyclosporine	Additive immunosuppression and potential for increased risk of infections.	Moderate
Vaccines (live)	Immunosuppression may impair immune response and increase risk of vaccine-induced disease.	High

Overdose & Toxicity Management

Signs of Toxicity:

Polyuria and polydipsia
Polyphagia
Hyperglycemia
Gastrointestinal ulceration
Electrolyte imbalances (hypokalemia, hypernatremia)
Hypertension
Behavioral changes
Adrenal suppression (with chronic overdose)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. For acute overdose, induce vomiting if oral ingestion and within 2 hours, and administer activated charcoal. Monitor and correct fluid and electrolyte imbalances. For chronic overdose, gradually taper the dose to avoid adrenal crisis. Provide supportive care, including gastrointestinal protectants (e.g., sucralfate, H2 antagonists) if ulceration is suspected. In severe cases, consider administration of exogenous ACTH to assess adrenal function.

Food Animal Withdrawal Times

🥩 Meat: 7 days🥛 Milk: 3 days

Withdrawal times may vary by country and formulation. For cattle, meat withdrawal is typically 7 days and milk withdrawal 3 days. For other food animals, consult local regulations. Not approved for use in laying hens in some countries.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in tightly closed container. Do not freeze injectable solutions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs, cats, and horses. Not approved for food animals in the US, but extra-label use is allowed under AMDUCA.

Extra-Label (Off-Label) Use: In the US, extra-label use of methylprednisolone in food animals is permitted under AMDUCA, but requires a valid veterinary-client-patient relationship and extended withdrawal times. Use in lactating dairy cattle is prohibited for certain formulations. In the EU, similar regulations apply under Regulation (EC) No 470/2009.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Methylprednisolone is a potent glucocorticoid used for its anti-inflammatory and immunosuppressive properties. It is commonly used in small animal practice for immune-mediated diseases and allergic conditions. In large animals, it is used for respiratory disease, musculoskeletal inflammation, and metabolic conditions like ketosis. Due to its potent effects, it should be used at the lowest effective dose for the shortest duration possible. Tapering is essential after prolonged therapy to avoid adrenal suppression. In food animals, strict adherence to withdrawal times is critical. Monitor for adverse effects, especially with long-term use. Consider alternative therapies for chronic conditions to minimize side effects.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)